Based on the provided sources, there is limited information available regarding the effects of lurbinectedin on fetal development. The sources primarily focus on other aspects of the drug, such as its patent status, mechanism of action, and clinical efficacy.

The first source, DrugPatentWatch, provides information about the patent status of lurbinectedin but does not mention anything about its impact on fetal development [1].

The second source, a study published in the National Center for Biotechnology Information (NCBI) database, discusses the mechanism of action and clinical use of lurbinectedin in the treatment of various cancers. However, it does not provide any information regarding the drug's effects on fetal development [2].

The third source is the FDA label for lurbinectedin, which provides detailed information about the drug's indications, dosage, and safety profile. While the label mentions the potential for lurbinectedin to cause fetal harm based on animal studies, it does not provide specific details about the extent or nature of the effects on fetal development [3].

Given the limited information available from the provided sources, it is not possible to draw a definitive conclusion about the effects of lurbinectedin on fetal development. To obtain more comprehensive and accurate information on this topic, it is recommended to consult additional reliable sources, such as scientific studies or consult a healthcare professional.

Sources:
[1] DrugPatentWatch. (n.d.). Lurbinectedin - Trademark Details. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Center for Biotechnology Information. (2021). Lurbinectedin - A New Drug for the Treatment of Small Cell Lung Cancer and Ovarian Cancer. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988166/
[3] U.S. Food and Drug Administration. (2020). FDA Label for Lurbinectedin. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf